Heim084990 • KOSDAQ
add
Helixmith Co Ltd
Við síðustu lokun
2.845,00 ₩
Dagbil
2.795,00 ₩ - 2.870,00 ₩
Árabil
2.500,00 ₩ - 7.440,00 ₩
Markaðsvirði
129,75 ma. KRW
Meðalmagn
73,24 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
KOSDAQ
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (KRW) | sep. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 1,80 ma. | 65,09% |
Rekstrarkostnaður | 5,81 ma. | -30,08% |
Nettótekjur | -3,79 ma. | 54,16% |
Hagnaðarhlutfall | -210,47 | 72,24% |
Hagnaður á hvern hlut | — | — |
EBITDA | -3,97 ma. | 24,02% |
Virkt skatthlutfall | — | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (KRW) | sep. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 70,45 ma. | -16,48% |
Heildareignir | 149,90 ma. | -34,10% |
Heildarskuldir | 6,08 ma. | -79,04% |
Eigið fé alls | 143,83 ma. | — |
Útistandandi hlutabréf | 46,05 m. | — |
Eiginfjárgengi | 0,91 | — |
Arðsemi eigna | -8,32% | — |
Ávöxtun eigin fjár | -8,66% | — |
Peningaflæði
Breyting á handbæru fé
| (KRW) | sep. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | -3,79 ma. | 54,16% |
Handbært fé frá rekstri | -4,52 ma. | 7,87% |
Reiðufé frá fjárfestingum | 32,00 ma. | 121,76% |
Reiðufé frá fjármögnun | -6,68 m. | 99,86% |
Breyting á handbæru fé | 27,80 ma. | 474,69% |
Frjálst peningaflæði | 523,28 m. | 107,32% |
Um
Helixmith Co. LTD. is a biotechnology company located in Seoul, South Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis, currently in phase III diabetic peripheral neuropathy in the US. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor, HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers, amyotrophic lateral sclerosis, coronary artery disease, claudication, and Charcot-Marie-Tooth disease. Wikipedia
Stofnsett
nóv. 1996
Vefsvæði
Starfsfólk
72
